Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHRTS trial of durvalumab after concurrent chemoradiotherapy in limited-stage small cell lung cancer
2026-525513-31-00Phase 3Authorised
- Sponsor
- NTNU
- Start
- Aug 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of durvalumab in small cell lung cancer (SCLC) (2 arms), sponsored by NTNU. Primary endpoint: Overall survival. Planned start Aug 2026; status: authorised.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2026-525513-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525513-31-00.